The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure

NCT07050706 | Enrolling By Invitation

• 4 other identifiers: PRMT5 and Heart Failure823004462022A1515111093RCBS20231211090745071
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.

Conditions

Heart Failure, Systolic

Keywords

PRMT5; Heart failure; cardiac function and cardiac structure

Outcome Measures

Primary Outcomes (11)

• Serum PRMT5 level at baseline

  Serum PRMT5 level is analysed at the day of informed consent agreement and blood sampling

  Baseline (day of informed consent agreement and blood sampling)

• LVIDs level at baseline

  Left ventricular internal diameter at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• LVIDd level at baseline

  Left ventricular internal diameter at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• LVPWs level at baseline

  left ventricular posterior wall at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• LVPWd level at baseline

  left ventricular posterior wall at diastole state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• IVSTs at baseline

  Interventricular septum at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• IVSTd at baseline

  Interventricular septum at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

  Baseline

• EF at baseline

  Ejection fraction is calculated according to the formula below: 1. EF=(LVEDV-LVESV)/LVEDV\*100%; 2. LVEDV=(7.0\*LVIDd\^3)/(2.4+LVIDd) 3. LVESV=(7.0\*LVIDs\^3)/(2.4+LVIDs)

  Baseline

• FS at baseline

  Fractional shortening is calculated based on the formula below: FS=(LVIDd-LVIDs)/LVIDd\*100%

  Baseline

• LVMi at baseline

  Left ventricular mass index is calculated according to the formula below: 1. LVMi(g/m\^2)=LVM/BSA; 2. LVM(g)=LVM=0.8×1.04×\[(LVIDd+IVSd+LVPWd)\^3-LVIDd\^3\]+0.6; 3. BSA(m\^2)=0.007184×W\^0.425×H\^0.725 (W: Weight, kg; H: Height, cm)

  Baseline

• RWT at baseline

  Relative wall thickness is calculated according to the formula below: RWT=2\*(IVSd+LVPWd)/LVIDd

  Baseline

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study evaluated whether serum PRMT5 levels could predict echocardiographic parameters in healthy controls and heart failure patients. A total of 50 participants in the healthy group and 50 in the heart failure group completed the study.

You may qualify if:

• Healthy group: Aged ≥18 years (both sexes), systolic blood pressure (SBP) ≤120 mmHg and diastolic blood pressure (DBP) ≤80 mmHg, no history of cardiovascular diseases, ejection fraction (EF) ≥50%.
• Heart failure group: Aged ≥18 years (both sexes), EF ≤50%.

Sponsors & Collaborators

• The University of Hong Kong-Shenzhen Hospital: lead

Study Sites (1)

the University of Hongkong-Shenzhen Hospital

Shenzhen, Guangdong, 518033, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Heart Failure, Systolic; Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Officials

• Assistant research fellow

  The University of HongKong-Shenzhen Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant research fellow

Study Record Dates

• First Submitted: June 13, 2025
• First Posted: July 3, 2025
• Study Start: January 1, 2025
• Primary Completion: December 31, 2025
• Study Completion (Estimated): December 31, 2026
• Last Updated: July 3, 2025

Record last verified: 2025-06

Locations

CN (1)